Metabolite Tales Blog

APRIL 4, 2023

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. Drug Metabolism and Disposition 50 (8) 1106-1118; DOI: [link] [4] Fell et al.,

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

Metabolite Tales Blog

JULY 5, 2023

Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. Synthetic macrocycles in oncology Pactritinib is a multi-kinase JAK2/FLT3 inhibitor used for the treatment of primary and secondary myelofibrosis, approved by the FDA in 2022. Chen et al.,

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. Synthetic macrocycles in oncology Pactritinib is a multi-kinase inhibitor used for the treatment of primary and secondary myelofibrosis and was approved by the FDA in 2022. Chen et al., 39, 1544-1556.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52